Anti-SH3PX1/SNX9 antibody [EPR14399]
- RabMAb
- Recombinant
- KO Validated
- What is this?
Be the first to review this product! Submit a review
|
(5 Publications)
Rabbit Recombinant Monoclonal SH3PX1/SNX9 antibody. Suitable for IP, WB, ICC/IF, Flow Cyt (Intra), IHC-P and reacts with Human, Mouse samples. Cited in 5 publications.
View Alternative Names
SH3PX1, SH3PXD3A, SNX9, Sorting nexin-9, SH3 and PX domain-containing protein 1, SH3 and PX domain-containing protein 3A, Protein SDP1
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
Immunofluorescent analysis of acetone-fixed HeLa cells labeling SH3PX1/SNX9 with ab181856 at 1/100 dilution followed by Goat anti rabbit IgG (Alexa Fluor®488) secondary antibody at 1/200 dilution. Counter stained with Dapi.
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
Intracellular flow cytometric analysis of 2%paraformaldehyde-fixedHeLa cells labeling SH3PX1/SNX9 with ab181856 at 1/10 dilution (red) compared to a Rabbit IgG monoclonal isotype control (green), followed by Goat anti rabbit IgG (FITC) secondary antibodyat 1/150 dilution.
- ICC/IF
Supplier Data
Immunocytochemistry/ Immunofluorescence - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
Immunofluorescent analysis of 4% paraformaldehyde-fixed HCT-116 cells labeling SH3PX1/SNX9 with ab181856 at 1/100 dilution followed by Goat anti rabbit IgG (Alexa Fluor®488) secondary antibody at 1/200 dilution. Counter stained with Dapi.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling SH3PX1/SNX9 with ab181856 at 1/250 dilution followed by prediluted HRP Polymer for Rabbit IgG. Counter stained with Hematoxylin.
Perform heat mediated antigen retrieval with EDTA buffer pH 9 before commencing with IHC staining protocol.
- IP
Supplier Data
Immunoprecipitation - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
Western blot analysis of HepG2 cell lysate immunoprecipitated using ab181856 at 1/50 dilution. Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate secondary antibody was used at 1/1000 dilution.
All lanes:
Immunoprecipitation - Anti-SH3PX1/SNX9 antibody [EPR14399] (ab181856)
Predicted band size: 67 kDa
false
- WB
Lab
Western blot - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
Lane 1 : Wild-type HAP1 cell lysate (20 μg)
Lane 2 : SH3PX1/SNX9 knockout HAP1 cell lysate (20 μg)
Lane 3 : HeLa cell lysate (20 μg)
Lane 4 : HCT116 cell lysate (20 μg)
Lanes 1 - 4 : Merged signal (red and green). Green - ab181856 observed at 75 kDa. Red - loading control, ab8245, observed at 37 kDa.
ab181856 was shown to specifically react with SH3PX1/SNX9 when SH3PX1/SNX9 knockout samples were used. Wild-type and SH3PX1/SNX9 knockout samples were subjected to SDS-PAGE. ab181856 and ab8245 (loading control to GAPDH) were diluted 1/1000 and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773)
and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.
All lanes:
Western blot - Anti-SH3PX1/SNX9 antibody [EPR14399] (ab181856)
Predicted band size: 67 kDa
false
- WB
Supplier Data
Western blot - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
All lanes:
Western blot - Anti-SH3PX1/SNX9 antibody [EPR14399] (ab181856) at 1/50000 dilution
All lanes:
HeLa cell lysate at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution
Predicted band size: 67 kDa
Observed band size: 78 kDa
false
- WB
Supplier Data
Western blot - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
All lanes:
Western blot - Anti-SH3PX1/SNX9 antibody [EPR14399] (ab181856) at 1/10000 dilution
All lanes:
HCT-116 cell lysate at 20 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugate at 1/1000 dilution
Predicted band size: 67 kDa
Observed band size: 78 kDa
false
- WB
CiteAb
Western blot - Anti-SH3PX1/SNX9 antibody [EPR14399] (AB181856)
SH3PX1/SNX9 western blot using anti-SH3PX1/SNX9 antibody [EPR14399] ab181856. Publication image and figure legend from Jarsch, I. K., Gadsby, J. R., et al., 2020, J Cell Biol, PubMed 32328641.
ab181856 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab181856 please see the product overview.
SNX9 in cells.(A) Single frame from a TIRFM time-lapse of Xenopus chordamesoderm cells expressing mNeonGreen-SNX9 (green) and GAP-RFP membrane marker (magenta) showing SNX9 at the tip of filopodia. Scale bar, 10 μm. (B) Western blots against SNX9 or the loading control DM1α (tubulin) of untreated RPE-1 cells and cells treated with either non-targeting control (Non-targ.) or anti SNX9 siRNA showing knockdown with the SNX9 siRNA sequence. (C) Quantification of the number of filopodia present per cell in untreated RPE-1 cells and cells treated with either nontargeting control or anti SNX9 siRNA, illustrating no change in the average number of filopodia per cell on SNX9 knockdown. Each data point represents an individual cell; n = 18, 13, and 23 cells for the untreated (unt.), non-targeting control (NT Cont.), and SNX9 siRNA–treated conditions, respectively. Lines indicate mean ± SD. Statistical significance was assessed by Kruskal-Wallis ANOVA with Dunn's multiple comparisons test. Overall ANOVA P = 0.1206 (n.s.), multiple comparisons : untreated vs. nontargeting control P = 0.1481 (n.s.), untreated vs. SNX9 siRNA P > 0.9999 (n.s.), nontargeting control vs. SNX9 siRNA P = 0.2800 (n.s.). (D and E) Example images of fluorescence confocal images of HeLa cells either (D) uninfected or (E) infected with C. trachomatis (yellow) and immunolabeled using mouse anti-human SNX9 (purple) and phalloidin (green), illustrating SNX9 presence in filopodia and how C. trachomatis stick to preexisting filopodia that contain SNX9 in either the tip or shaft of the filopodia. Scale bars, 2 μm. (F) Quantification of SNX9 presence in filopodia in both uninfected HeLa cells and in cells infected with C. trachomatis. SNX9 immunolabeling stains ~95% of filopodia in untreated RPE-1 with no difference on C. trachomatis infection. Each data point represents an individual imaging region; n = 20 regions per condition. Lines indicate mean ± SD. Infected : 2,080 filopodia from 97 cells; uninfected : 1,648 filopodia from 126 cells. Statistical significance was assessed by unpaired t test, P = 0.3239 (n.s.).
false
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purity
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
Functions of SNX9 extend to cellular endocytosis and membrane remodeling. It is part of the retromer complex which plays a role in sorting endosomal proteins back to the trans-Golgi network or plasma membrane. SNX9 facilitates the curvature of cellular membranes aiding the process of clathrin-mediated endocytosis. This protein's ability to bind with both phospholipids and cytoskeletal components highlights its importance in maintaining cellular architecture and facilitating signal transduction.
Pathways
SNX9 integrates into the endocytic and signaling pathways. Its involvement in clathrin-mediated endocytosis and interactions with proteins like dynamin and WASP indicate its key role in vesicle formation and intracellular transport. SNX9 also participates within the Wnt signaling pathway functioning alongside proteins like LRP6 and GSK3 to mediate signal transduction processes that regulate cell fate determination. These pathways underline SNX9’s significance in processes controlling cellular growth and differentiation.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (5)
Recent publications for all applications. Explore the full list and refine your search
The EMBO journal 43:5857-5882 PubMed39420093
2024
Applications
Unspecified application
Species
Unspecified reactive species
eLife 11: PubMed35050850
2022
Applications
Unspecified application
Species
Unspecified reactive species
The international journal of biochemistry & cell b 129:105863 PubMed33049375
2020
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of cell biology 219: PubMed32328641
2020
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of biological chemistry 293:8077-8088 PubMed29622675
2018
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com